Prevalence and National Patterns of Commonly Prescribed Antidepressants and other Psychotropic Medications to patients with treatment-resistant depression in France
Abstract Background Prevalence of Treatment-Resistant Depression (TRD) varied widely across studies due to heterogeneous definitions. Several treatment strategies exist to manage patients with TRD but evidence from real-world data is scarce. Investigating their use in real-life settings is important to understand national prescribing practices and to refine prevalence estimation.Method All adult patients (≥ 18 years) with a TRD episode for the year 2019 were identified in a sample of four French regions accounting for 27% of national individuals. After exclusion of patients with psychotic or bipolar disorders, Parkinson’s disease, and dementia, TRD was defined by i/ 3 successive sequences of different antidepressants (AD), or ii/ the dispensing of several different AD together, or iii/ an AD with a potentiator (lithium, antiepileptic drugs, or antipsychotic drugs) over the same treatment period. The prevalence rate was estimated for the year 2019 and treatment patterns were described by treatment class and molecule.Results For the year 2019, 66,810 patients were identified with TRD, accounting for 23.9% of all patients treated for depression. The mean age was 56 years (±15.9) with 63.7% of women. Standardized prevalence of TRD was estimated at 35.1 per 10 000 patients, and 25.8 per 10,000 patients when excluding patients probably treated for another primary diagnosis than depression. Association of an AD with an antipsychotic was the most frequently used strategy, with SSRIs and second-generation antipsychotics being the most often prescribed.Conclusion This study provides robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as potentiator of antidepressants..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 10. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alexandre, Vimont [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.01.18.24301467 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042222567 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042222567 | ||
| 003 | DE-627 | ||
| 005 | 20240211090425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.01.18.24301467 |2 doi | |
| 035 | |a (DE-627)XBI042222567 | ||
| 035 | |a (biorXiv)10.1101/2024.01.18.24301467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alexandre, Vimont |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence and National Patterns of Commonly Prescribed Antidepressants and other Psychotropic Medications to patients with treatment-resistant depression in France |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Prevalence of Treatment-Resistant Depression (TRD) varied widely across studies due to heterogeneous definitions. Several treatment strategies exist to manage patients with TRD but evidence from real-world data is scarce. Investigating their use in real-life settings is important to understand national prescribing practices and to refine prevalence estimation.Method All adult patients (≥ 18 years) with a TRD episode for the year 2019 were identified in a sample of four French regions accounting for 27% of national individuals. After exclusion of patients with psychotic or bipolar disorders, Parkinson’s disease, and dementia, TRD was defined by i/ 3 successive sequences of different antidepressants (AD), or ii/ the dispensing of several different AD together, or iii/ an AD with a potentiator (lithium, antiepileptic drugs, or antipsychotic drugs) over the same treatment period. The prevalence rate was estimated for the year 2019 and treatment patterns were described by treatment class and molecule.Results For the year 2019, 66,810 patients were identified with TRD, accounting for 23.9% of all patients treated for depression. The mean age was 56 years (±15.9) with 63.7% of women. Standardized prevalence of TRD was estimated at 35.1 per 10 000 patients, and 25.8 per 10,000 patients when excluding patients probably treated for another primary diagnosis than depression. Association of an AD with an antipsychotic was the most frequently used strategy, with SSRIs and second-generation antipsychotics being the most often prescribed.Conclusion This study provides robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as potentiator of antidepressants. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Margot, Biscond |4 aut | |
| 700 | 1 | |a Henri, Leleu |4 aut | |
| 700 | 1 | |a Sanchez-Rico², Marina |4 aut | |
| 700 | 1 | |a Nicolas, Hoertel |4 aut | |
| 700 | 1 | |a Pierre-Michel, Llorca |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 10. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.01.18.24301467 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 02 | ||